Sintilimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-PD-1 monoclonal antibody IBI308 |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China.
It is a fully human IgG4 monoclonal antibody that binds to programmed cell death protein 1.
It was jointly developed by Innovent Biologics and Eli Lilly.